<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264133</url>
  </required_header>
  <id_info>
    <org_study_id>CLV-411</org_study_id>
    <secondary_id>CLV-411</secondary_id>
    <nct_id>NCT01264133</nct_id>
  </id_info>
  <brief_title>A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B</brief_title>
  <official_title>An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open study to Evaluate the Efficacy, Safety and Sustained effect of Clevudine monotherapy
      or Adefovir and Clevudine combination in proportion to Roadmap concept in Patients with
      chronic hepatitis B.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA levels ＜ 60 IU/mL</measure>
    <time_frame>48 week</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine, Adefovir</intervention_name>
    <description>Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is 18 years and older.

          2. Patient is documented to be HBsAg positive for &gt; 6 months.

          3. Patient is HBV DNA positive with DNA levels ≥ 2,000 IU/mL within 30 days of baseline.

          4. Patient has ALT levels &gt;=80 IU/L

          5. Patient with compensated liver disease (Patient with chronic B Hepatitis or liver
             cirrhosis &lt;= 6)

          6. Patient who is able to give written informed consent prior to study start and to
             comply with the study requirements.

        Exclusion Criteria:

          1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or
             corticosteroid therapy.

          2. Patients previously treated with interferon, peg-interferon or other immunomodulatory
             within the previous 6 months.

          3. Patients previously treated with clevudine, lamivudine, adefovir, entecavir,
             telbivudine or any other investigational nucleoside for HBV infection.

          4. Patient is coinfected with HCV, HDV or HIV.

          5. Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.

          6. Patient with clinical evidence of decompensated liver disease or hepatocellular
             carcinoma

          7. Patient with previous liver transplantation

          8. Patient is pregnant or breast-feeding.

          9. Patient has a clinically relevant history of abuse of alcohol or drugs.

         10. Patient has a significant immunocompromised, gastrointestinal, renal, hematological,
             psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone,
             neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness
             that in the investigator's opinion might interfere with therapy.

         11. Patient has creatinine clearance less than 60mL/min as estimated by the following
             formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note:
             multiply estimates by 0.85 for women]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <name_title>Byungchul Yoo</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

